The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.
SomaLogic, a US-based health-management platform developer backed by corporate investors Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics, has added $81m to a series A round now totalling $214m.
Casdin Capital is leading the round, with Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium Management backing the latest tranche.
The first close included Farallon Capital Management, Foresite Capital, Blue Water Life Science Advisors, Madryn Asset Management, Fiscus Ventures, Reimagined…
